# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian cancer

Cancer, Ovarian
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 71-80 of 622 results.
Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer
Status: Not yet recruiting
Last Changed: Apr 24, 2020
First Received: Apr 24, 2020
Disease(s): Advanced Ovarian Cancer
Intervention(s): Tranexamic Acid, normal saline
Locations: Shanghai Cancer Center, Fudan University, Shanghai, Shanghai, China
A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
Status: Recruiting
Last Changed: Oct 17, 2018
First Received: Oct 17, 2018
Disease(s): Ovarian Cancer
Intervention(s): ZL-2306 (Nirapairb), Placebo Comparator
Locations: Anhui Provincal Hospital, Hefei, Anhui, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
The first affiliated hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Guizhou Cancer hospital, Guiyang, Guizhou, China
... and 26 other locations.
OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)
Status: Not yet recruiting
Last Changed: May 15, 2020
First Received: May 15, 2020
Disease(s): Ovarian Cancer Metastatic
Intervention(s): cyclophosphamide, fludarabine, IL-2 (Proleukin), Unmodified Tumour Infiltrating Lymphocytes (UTIL-01), Gene modified Tumour Infiltrating Lymphocytes (CoTIL-01)
Locations: Queens Elizabeth Hospital, Birmingham, United Kingdom
The Christies Hospital, Manchester, United Kingdom
Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer
Status: Not yet recruiting
Last Changed: May 29, 2018
First Received: May 29, 2018
Disease(s): Ovarian Cancer
Intervention(s): Pembrolizumab, Gemcitabine, Paclitaxel, Liposomal Doxorubicin
Locations: National Cancer Institute, Milan, Italy
CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients
Status: Not yet recruiting
Last Changed: May 28, 2020
First Received: May 10, 2019
Disease(s): Ovarian Cancer, Resistant BRCA Wild-Type Ovarian Cancer
Intervention(s): Cohort 1: Dose Escalation, Cohort 2: Dose Escalation
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
Status: Recruiting
Last Changed: Dec 03, 2019
First Received: Nov 08, 2018
Disease(s): Ovarian Cancer Recurrent
Intervention(s): Rintatolimod, Pembrolizumab, Cisplatin
Locations: Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.
Status: Recruiting
Last Changed: May 15, 2020
First Received: Apr 11, 2017
Disease(s): Epithelial Ovarian Cancer
Intervention(s): Active Comparator: Olaparib tablets, Placebo
Locations: Research Site, Brussels, Belgium
Research Site, Leuven, Belgium
Research Site, Liège, Belgium
Research Site, Namur, Belgium
Research Site, London, Ontario, Canada
... and 101 other locations.
ASA in Prevention of Ovarian Cancer (STICs and STONEs)
Status: Recruiting
Last Changed: Apr 14, 2020
First Received: Mar 29, 2018
Disease(s): Ovarian Cancer Prevention
Intervention(s): Acetylsalicylic acid, Placebo
Locations: Prince of Wales Hospital, Randwick, New South Wales, Australia
Westmead Hospital, Westmead, New South Wales, Australia
Peter McCallum Cancer Institute, Melbourne, Victoria, Australia
Tom Baker Cancer Centre, Calgary, Alberta, Canada
Clinical Research Unit at Vancouver Coastal, Vancouver, British Columbia, Canada
... and 11 other locations.
Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.
Status: Recruiting
Last Changed: Dec 12, 2019
First Received: Jan 19, 2015
Disease(s): Ovarian Cancer
Intervention(s): BRCA genetic data
Locations: Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer
Status: Not yet recruiting
Last Changed: Jan 31, 2019
First Received: Oct 02, 2018
Disease(s): Epithelial Ovarian Cancer
Intervention(s): anti-Mesothelin Car NK Cells